FDA classifies over-the-counter sleep apnea risk devices as class II

The Food and Drug Administration has formally created a regulatory category for the consumer devices that tell users they may be at risk of sleep apnea. In a final order published in the Federal Register on 30 October 2026, the agency classified the "over-the-counter device to assess risk of sleep apnea" into class II, subject to special controls, and codified the classification at 21 CFR 868.2378 [s1]. The order is effective 30 October 2026, under docket number FDA-2026-N-12385 [s1].

What the device is

The FDA defines the new generic device type as one "intended to provide a notification of the risk of sleep apnea in users who have not been previously diagnosed with sleep apnea" [s1]. Such a device uses software algorithms to analyse input sensor signals and produce a risk assessment [s1].

The order draws a firm line around what the device is not. It is "not intended to provide a standalone diagnosis, replace traditional methods of diagnosis (e.g., polysomnography), assist clinicians in diagnosing sleep disorders, or be used as an apnea monitor" [s1]. In other words, it is a screening or risk-flagging tool for undiagnosed users, not a substitute for a sleep study.

How the classification happened

The category traces back to a specific product. On 31 May 2023, the FDA received a request from Samsung Electronics Co., Ltd. for De Novo classification of a "Sleep Apnea Feature," and on 6 February 2024 the agency issued an order classifying the device into class II [s1]. This 30 October final order codifies that classification into the Code of Federal Regulations [s1].

De Novo is the pathway the FDA uses for a novel device that has no existing predicate to compare against. By law, a device not in commercial distribution before 28 May 1976 is automatically placed in class III — the highest-risk category, which requires premarket approval — "regardless of the level of risk posed by the new device," until the agency acts to classify or reclassify it [s1]. The De Novo process let the FDA move the sleep-apnea-risk device into class II instead, which the agency says enhances patient access to beneficial innovation by reducing regulatory burden [s1].

Why class II, and what special controls mean

The FDA classifies a device into class II when general controls alone are not enough to assure its safety and effectiveness, but "special controls" can be defined that, together with the general controls, provide that assurance [s1]. The order lists the risks it is guarding against — among them a false negative that delays evaluation or treatment, a false positive that triggers unnecessary procedures, and over-reliance on the device output leading a user to forgo care [s1].

Against those risks the order sets out detailed special controls. Clinical performance testing must use a study population representative of the intended users, evaluate performance across subgroups such as age, sex, body mass index and skin tone, and compare the device against a clinical comparator such as polysomnography [s1]. For devices using machine-learning algorithms, clinical validation must be done on a dataset separate from the training dataset [s1]. The controls also require non-clinical performance testing, electrical and electromagnetic safety testing, biocompatibility of any skin-contacting parts, software verification and validation, human-factors testing, and specific labelling — including a statement that the device does not replace polysomnography and is not an apnea monitor [s1].

It still needs a submission

Classifying the device type into class II does not exempt it from premarket review. The FDA states that it has not determined these devices should be exempt under section 510(m) of the statute, so an over-the-counter sleep-apnea-risk device is "subject to premarket notification requirements under section 510(k)" [s1]. Because the device is now classified, however, it can serve as a predicate for future devices of the same type, letting other developers use the lighter 510(k) route rather than a fresh De Novo request or premarket approval [s1].

What is settled and what is not

What is fixed is concrete: a dated final order now exists, a new device category is codified at 21 CFR 868.2378 with named special controls, and the classification is effective immediately [s1]. The order also makes clear what these consumer tools may and may not claim — a risk notification for the undiagnosed, not a diagnosis [s1].

What the order does not change is the clinical bar for diagnosing sleep apnea, which still rests on established methods such as polysomnography [s1]. The classification governs how these risk-assessment devices reach the market and what evidence their makers must show; it does not turn a consumer alert into a medical diagnosis [s1].